Procan Technologies
- Diagnostics
- Other R&D services
- CMO, CRO
ProCan® Technologies, a global leader in cancer proteomics, now offers the
TargetQuantTM ADC Panel to support the development of ADCs across solid tumors.
ProCan Technologies leverages proteomic insights to enhance the outcomes of oncology research and clinical trials globally. Having developed world leading high throughput mass spectrometry methodologies, ProCan has analysed over 29,000 tumour samples in collaboration with more than 100 groups across the globe. The data comprises the world’s largest proteomic oncology database generated from a single platform. ProCan Technologies now offers the TargetQuant ADC panel, a mullti-plexed, targeted panel to directly quantify ADC target expression enabling improved patient selection into ADC clinical trials and personalised precision oncology.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}